A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer
| Autor: | Toshiyuki Sawa, Daizo Kaito, Akane Horiba, Takaaki Hasegawa, Yasuhi Ohno, Toshitaka Suzuki, Shinya Hayashi, Takayoshi Iida, Tatsuo Kato, Yohei Futamura, Tsutomu Yoshida |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Lung Neoplasms Paclitaxel Health Toxicology and Mutagenesis medicine.medical_treatment Urology Phases of clinical research Carboplatin 03 medical and health sciences chemistry.chemical_compound nab-paclitaxel 0302 clinical medicine Albumins Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Lung cancer radiotherapy Aged Aged 80 and over Chemotherapy Radiation business.industry Common Terminology Criteria for Adverse Events Chemoradiotherapy Middle Aged Thorax medicine.disease Survival Analysis non–small-cell lung cancer Surgery Radiation therapy 030104 developmental biology Treatment Outcome chemistry Oncology Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Female Neoplasm Grading business |
| Zdroj: | Journal of Radiation Research |
| ISSN: | 1349-9157 |
| Popis: | We investigated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) with concurrent radiotherapy for unresectable locally advanced non-small-cell lung cancer (NSCLC). Patients with Stage III NSCLC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Concurrent chemoradiotherapy consisted of weekly administration of nab-PTX (40 mg/m(2)) plus CBDCA (area under the plasma concentration time curve (AUC) 2) and thoracic radiotherapy (60 Gy/30 fractions) for a total of 6 weeks. After concurrent chemoradiotherapy, patients received an additional two cycles of consolidation phase chemotherapy that consisted of 4-week cycles of nab-PTX (100 mg/m(2) on Days 1, 8 and 15)/CBDCA (AUC 5 mg/ml/min on Day 1). Response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors. Progression-free survival and overall survival were estimated using the Kaplan-Meier method. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events. A total of 10 patients were enrolled in this trial between September 2013 and January 2014 from three institutes. The overall response rate was 40.0% and the median progression-free survival was 6.7 months. Treatment-related death occurred in two patients. Grade 2 or worse severe radiation pneumonitis was observed in all three patients that had the volume of lung receiving at least 20 Gy (V20) >30%. The results of this study indicate that no further investigation is warranted into nab-PTX and CBDCA with concurrent thoracic radiation for Stage III NSCLC with V20 > 30% due to severe toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|